Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Advances in Experimental Medicine and Biology|October 28, 2022
Magnetic Resonance Imaging BasicsAtul Singh Minhas, Ruth Oliver
Advances in Experimental Medicine and Biology|October 28, 2022
Magnetic Resonance Electrical Properties Tomography (MREPT)Ulrich Katscher, Atul Singh Minhas, Nitish Katoch
Advances in Experimental Medicine and Biology|October 28, 2022
Electromagnetic Properties and the Basis for CDI, MREIT, and EPTRosalind Sadleir, Camelia Gabriel, Atul Singh Minhas
Magnetic Resonance in Medicine|February 3, 2021
High-frequency electrical properties tomography at 9.4T as a novel contrast mechanism for brain tumorsClémentine Lesbats, Nitish Katoch, Atul Singh Minhas, et al.
Magnetic Resonance in Medicine|March 7, 2018
Measurement of blood-brain barrier permeability using dynamic contrast-enhanced magnetic resonance imaging with reduced scan timeJonghyun Bae, Jin Zhang, Youssef Zaim Wadghiri, et al.
Clinical Neuropharmacology|November 4, 2008
Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's diseaseDebra Tompson, Ruth Oliver-Willwong
IEEE Reviews in Biomedical Engineering|October 16, 2019
Automated Brain Tumor Segmentation Using Multimodal Brain Scans: A Survey Based on Models Submitted to the BraTS 2012-2018 ChallengesMina Ghaffari, Arcot Sowmya, Ruth Oliver
CPT: Pharmacometrics & Systems Pharmacology|November 4, 2021
Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinicRocio Lledo-Garcia, Kate Dixon, Anthony Shock, et al.
Journal of Clinical Pharmacology|December 1, 2022
Population Pharmacokinetics and Exposure-Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus ErythematosusChayan Acharya, Mats O Magnusson, Pavan Vajjah, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I studyKosmas Kretsos, Georg Golor, Astrid Jullion, et al.
Pageof 2